Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Launches Amgen's Bevacizumab In Japan

Comes Shortly After Pfizer Debuted First Japanese Avastin Rival

Executive Summary

Daiichi Sankyo has introduced Amgen’s bevacizumab biosimilar in Japan, hot on the heels of Pfizer’s launch of its own rival to Avastin in the country.

You may also be interested in...



Samsung Bioepis Bevacizumab Nod Sets Stage For EU Throwdown

Samsung Bioepis has received a pan-European endorsement from the CHMP for its Aybintio bevacizumab biosimilar. The nod follows two previous European Avastin biosimilar approvals, with market formation believed to be imminent.

Pfizer Launches US Bevacizumab At A 23% Discount

Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.

Daiichi Sankyo Begins Shipping Amgen’s Trastuzumab Biosimilar In Japan

Partnership inked between the Japanese and US players in July 2016 results in Daiichi Sankyo launching its first biosimilar product.

Topics

Related Companies

UsernamePublicRestriction

Register

GB149477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel